FR23C1025I1 - METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY - Google Patents

METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY

Info

Publication number
FR23C1025I1
FR23C1025I1 FR23C1025C FR23C1025C FR23C1025I1 FR 23C1025 I1 FR23C1025 I1 FR 23C1025I1 FR 23C1025 C FR23C1025 C FR 23C1025C FR 23C1025 C FR23C1025 C FR 23C1025C FR 23C1025 I1 FR23C1025 I1 FR 23C1025I1
Authority
FR
France
Prior art keywords
methods
cell therapy
barr virus
associated lymphoproliferative
lymphoproliferative syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1025C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56027234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of FR23C1025I1 publication Critical patent/FR23C1025I1/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR23C1025C 2015-05-12 2023-06-14 METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY Active FR23C1025I1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160549P 2015-05-12 2015-05-12
PCT/US2016/031784 WO2016183153A1 (en) 2015-05-12 2016-05-11 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Publications (1)

Publication Number Publication Date
FR23C1025I1 true FR23C1025I1 (en) 2023-07-21

Family

ID=56027234

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1025C Active FR23C1025I1 (en) 2015-05-12 2023-06-14 METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY

Country Status (19)

Country Link
US (1) US10568908B2 (en)
EP (1) EP3294304B1 (en)
JP (2) JP7284556B2 (en)
KR (1) KR102666781B1 (en)
CN (1) CN107835690A (en)
AR (1) AR104598A1 (en)
AU (1) AU2016262484B2 (en)
BR (1) BR112017024431B1 (en)
CA (1) CA2984178C (en)
CL (1) CL2017002846A1 (en)
FR (1) FR23C1025I1 (en)
HK (1) HK1244697A1 (en)
IL (1) IL255581B (en)
MX (1) MX2017014257A (en)
NZ (1) NZ736675A (en)
PH (1) PH12017501993A1 (en)
RU (1) RU2720245C2 (en)
WO (1) WO2016183153A1 (en)
ZA (1) ZA201707335B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756276C2 (en) 2016-05-25 2021-09-29 Дзе Каунсил Оф Дзе Квинсленд Инститьют Оф Медикал Рисерч Immunotherapy methods
US20190194619A1 (en) * 2016-09-16 2019-06-27 Baylor College Of Medicine Platform for activation and expansion of virus-specific t-cells
JP2021500360A (en) * 2017-10-23 2021-01-07 アタラ バイオセラピューティクス，インコーポレーテッド How to Manage Tumor Flare in Adoptive Immunotherapy
CN108220237B (en) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 Human NK/T cell line
EP3737394A4 (en) * 2018-01-08 2021-11-10 Atara Biotherapeutics, Inc. Systems and methods for distributing cell therapies
WO2019178170A1 (en) 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
EP4048780A4 (en) * 2019-10-23 2024-03-13 The Council of the Queensland Institute of Medical Research Adoptive immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
WO2004093905A1 (en) * 2003-04-16 2004-11-04 City Of Hope Human cytomegalovirus antigens expressed in mva and methods of use
JP4824389B2 (en) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof
ES2615861T3 (en) 2008-10-30 2017-06-08 Yeda Research And Development Company Ltd. Anti-third-party central memory T cells, their production methods and their use in transplantation and disease treatment
AU2011295845B2 (en) 2010-09-01 2016-09-22 Baylor College Of Medicine EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC)
WO2013169386A1 (en) * 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
EP3872097A1 (en) * 2012-10-19 2021-09-01 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
CA2926859A1 (en) * 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
ES2846747T3 (en) * 2014-11-05 2021-07-29 Memorial Sloan Kettering Cancer Center Procedures for selecting the T cell line and its donor for adoptive cell therapy
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Also Published As

Publication number Publication date
ZA201707335B (en) 2021-02-24
BR112017024431B1 (en) 2021-10-13
AU2016262484A1 (en) 2018-01-04
MX2017014257A (en) 2018-04-20
KR20180003575A (en) 2018-01-09
EP3294304A1 (en) 2018-03-21
US20180125891A1 (en) 2018-05-10
CN107835690A (en) 2018-03-23
JP2018520095A (en) 2018-07-26
AR104598A1 (en) 2017-08-02
BR112017024431A2 (en) 2018-07-24
AU2016262484B2 (en) 2021-10-21
RU2017143151A3 (en) 2019-10-29
US10568908B2 (en) 2020-02-25
WO2016183153A1 (en) 2016-11-17
HK1244697A1 (en) 2018-08-17
JP2021119154A (en) 2021-08-12
CL2017002846A1 (en) 2018-05-25
JP7284556B2 (en) 2023-05-31
RU2720245C2 (en) 2020-04-28
IL255581B (en) 2021-03-25
RU2017143151A (en) 2019-06-13
NZ736675A (en) 2023-03-31
IL255581A (en) 2018-01-31
CA2984178C (en) 2023-10-31
PH12017501993A1 (en) 2018-03-26
CA2984178A1 (en) 2016-11-17
KR102666781B1 (en) 2024-05-20
EP3294304B1 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
FR23C1025I1 (en) METHODS OF TREATING EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE SYNDROMES USING T-CELL THERAPY
ZA201903906B (en) Phosphoramidates for the treatment of hepatitis b virus
DK3597646T3 (en) THERAPEUTIC COMPOUNDS SUITABLE FOR THE PROHYPHYLACTIC OR THERAPEUTIC TREATMENT OF AN HIV VIRUS INFECTION
HRP20190352T1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
MA40867A (en) METHODS FOR THE TREATMENT OF FILOVIRIDAE VIRAL INFECTIONS
ES2973267T3 (en) Virus purification
HK1223931A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
MA50264A (en) METHODS OF TREATING HEPATITIS B INFECTIONS
IL289655A (en) Compounds useful to treat influenza virus infections
DK3294740T3 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of viral infection
MA43925A (en) Hepatitis B virus treatment process
DK3137078T3 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
DK3370723T3 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
DK3352857T3 (en) SYD985 TREATMENT OF T-DM1 REFRACTORY CANCER PATIENTS
MA46967A (en) METHODS OF TREATMENT OF HEMOPHILIC ARTHROPATHY USING CHEMERICAL COAGULATION FACTORS
DK3471732T3 (en) LIPOSOMES FOR THE TREATMENT OF VIRUS INFECTIONS
IL288713A (en) Methods to treat viral infections
ZA201804025B (en) Inactivation of viruses by delipidation
EA201791356A1 (en) PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection